Imagine a future where broken genes can be repaired. That's the ambitious premise behind Editas Medicine, the clinical stage genome editing company that has now raised $120.0M in Series b funding.
The company is focused on translating the power of CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments. This capital will support its goal to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of serious diseases.















